PubMed HealthSearch

PubMed · 8847362

Complement activation on thiol-modified gold surfaces.

Abstract

To evaluate the importance of protein adsorption and chemical composition of the solid surface on complement activation, we used mercaptoglycerol (MG) and mercaptopropionic acid (MPA) modified gold surfaces as model surfaces. The complement activation by these surfaces was determined by measuring fluid phase iC3b and C5b-9 in serum that had been in contact with the surfaces. In addition, "active" C3 deposition at the modified surfaces was measured with the use of ellipsometry, an optical technique. It was found that the MG surface caused pronounced productions of iC3b and C5b-9 in serum as well as increased C3 deposition on the surface. In contrast, the bare gold surface and the MPA surface caused very little complement activation. The MG surface seems to have a high affinity with immunoglobulin G (IgG) that may be one explanation for the high complement activation ability of the MG surface. However, complement activation at the MG surface was relatively insensitive to Mg-EGTA buffer at a high serum concentration, indicating alternative pathway activation when classical pathway activation was inhibited. Corresponding control experiments performed with Mg-EGTA serum at hydrophobic silicon surfaces precoated with IgG showed no sign of alternative pathway activation. At a lower serum concentration, classical pathway activation seemed to dominate at the MG surface and the hydrophobic silicon surface precoated with IgG. Most probably, it is the hydroxyl groups at the MG surface that are associated with alternative pathway activation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L Liu, H Elwing. 1996. Complement activation on thiol-modified gold surfaces.. https://doi.org/10.1002/(sici)1097-4636(199604)30%3A4%3C535%3A%3Aaid-jbm12%3E3.0.co%3B2-g

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

N-(benzyloxycarbonyl)glycine esters and amides as new anticonvulsants.

Glycine is a small neutral amino acid exhibiting weak anticonvulsant activities in vivo. Recently, studies have demonstrated that N-(benzyloxycarbonyl)glycine (1) antagonized seizures superior to glycine in addition to activity in the maximal electroshock (MES) test, a convulsive model where glycine is inactive. In the present study a series of ester and amide derivatives of 1 as well as esters of N-(3-phenylpropanoyl)glycine (5) have been prepared. The compounds were evaluated in the MES test as well as in several chemically induced seizure models. Among the derivatives investigated, N-(benzyloxycarbonyl)glycine benzylamide (16) was the most potent compound exhibiting an anticonvulsant activity in the MES test comparable to the drug phenytoin. Median effective doses (ED50) of 4.8 and 11.6 mg/kg were determined at 30 min and 3 h after i.p. administration, respectively. Compound 16 also effectively suppressed tonic seizures in different chemically induced models such as the strychnine, 3-mercaptopropionic acid, and pentylenetetrazole tests. Moreover, the compound studied here did not show acute neurotoxicity in the rotorod test up to a dose of 150 mg/kg. It is concluded that N-(benzyloxycarbonyl)glycine amides, especially 16, are potent anticonvulsant agents.

3-Mercaptopropionic Acid

CNS adenosine A1 receptors are altered after the administration of convulsant 3-mercaptopropionic acid and cyclopentyladenosine: an autoradiographic study.

Rat CNS adenosine A1 receptors were studied by quantitative autoradiography after the administration of convulsant 3-mercaptopropionic acid (MP) and an adenosine analogue cyclopentyladenosine (CPA), using 2-chloro-N6-[cyclopentyl-2,3,4,5-3H adenosine]-([3H]CCPA) as radioactive ligand. Specific binding was quantified in hippocampus, cerebellum, cerebral cortex, thalamic nuclei, superior colliculus and striatum, and the highest densities were found in CA1, CA2, and CA3 hippocampus subareas and the lowest levels in superior colliculus and striatum. MP administration (150 mg/kg, i.p.) produced significant increases in [3H]CCPA binding in CA1 subarea at seizure (15%) and postseizure (21%) and in CA2 at seizure (15%) but a tendency to decrease in dentate gyrus. There was an increase in cerebellum at seizure (18%) but no significant changes in the other studied regions. CPA injection (2 mg/kg, i.p.) enhanced [3H]CCPA binding in CA1 and CA2 areas (17-18%) but not in CA3 area of the hippocampus. When CPA was administered before MP, which delayed seizure onset, an increase in [3H]CCPA binding in CA1 hippocampus subarea (19%) and cerebellum (28%) was also observed. Results showed that the administration of convulsant MP and adenosine analogue CPA exerts differential effects on adenosine A1 receptors in CNS areas; hippocampus is the most affected area with all treatments, specially CA1 subarea, supporting an essential role in convulsant activity as well as in seizure prevention.

3-Mercaptopropionic Acid

Biphasic response to bradykinin in isolated porcine iliac arteries is mediated by bradykinin B1 and B2 receptors.

Bradykinin-induced responses were studied in isolated porcine iliac arteries. Relaxation was endothelium dependent and seen at low concentrations (10(-10)-10(-8) M) of bradykinin. It was inhibited by the bradykinin B2-receptor antagonist icatibant (HOE-140) and by the nitric oxide synthase inhibitor Nomega-nitro-L-arginine. Bradykinin-induced relaxation was significantly potentiated by the kininase I carboxypeptidase inhibitor mergepta (10(-6) M). Bradykinin (>10(-7) M) elicited contraction of preparations with or without endothelium. The contraction was abolished by indomethacin but was not affected by the thromboxane A2/prostaglandin H2-receptor antagonist SQ 29,548. Icatibant and the bradykinin B1-receptor antagonist desArg9[Leu8]bradykinin significantly decreased bradykinin-induced contraction regardless of endothelial function. The contraction also was decreased by treatment with mergepta. The bradykinin B1-receptor agonist desArg9-bradykinin contracted endothelium-denuded arterial strips. This contraction was significantly decreased by desArg9[Leu8]bradykinin but not by icatibant. The desArg9-bradykinin-induced contraction also was inhibited by the protein-synthesis inhibitor cycloheximide. Neither bradykinin-induced relaxation nor contraction was affected by the ACE inhibitors enalaprilat or cilazaprilat. In conclusion, bradykinin-induced relaxation of isolated porcine iliac arteries was mediated by endothelial bradykinin B2 receptors and mainly nitric oxide. Bradykinin-induced contraction was endothelium independent, indomethacin sensitive, and probably mediated by bradykinin B1 (inducible) and B2 receptors located in the vascular smooth-muscle layer. Kininase I carboxypeptidase, and not ACE, is the main enzyme responsible for bradykinin degradation in these vessels.

3-Mercaptopropionic Acid